Pluristem Therapeutics marks its first entry into the defense sector with today’s breaking news. NIAID, a part of the U.S. National Institutes of Health (NIH), will initiate studies in large animals to evaluate dosing for Pluristem’s PLX-R18 as a medical countermeasure in the treatment of the hematologic components of Acute Radiation Syndrome (ARS).
To learn more, read the full press issued by Pluristem, included below with permission from Janet Vasquez, Managing Director/Founder of JVPRVY. [Read more…]